文献速递炎症性肠病

系统评价与网络Meta分析:中重度溃疡性结肠炎的一线和二线药物治疗

Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2017-12-04

该系统评价与网络Meta分析纳入成人中重度溃疡性结肠炎随机对照试验,间接比较抗TNF药物、抗整合素药物和JAK抑制剂的疗效与安全性。生物制剂初治患者中,英夫利西单抗和维得利珠单抗在诱导临床缓解和黏膜愈合方面排名最高;既往暴露于抗TNF患者中,托法替尼排名最高。维得利珠单抗在维持治疗中安全性排名最高。

要点

  • 生物制剂初治患者中,英夫利西单抗和维得利珠单抗在诱导临床缓解和黏膜愈合方面排名最高。
  • 既往暴露于抗TNF患者中,托法替尼在诱导临床缓解和黏膜愈合方面排名最高。
  • 维得利珠单抗在维持治疗中严重不良事件和感染方面安全性排名最高。

核心结论

  • 基于间接比较,英夫利西单抗和维得利珠单抗作为一线药物排名最高,托法替尼作为二线药物排名最高,用于中重度溃疡性结肠炎患者的缓解诱导和黏膜愈合。
  • 需要头对头试验以更有信心地为临床决策提供信息。

研究设计与样本

  • 系统评价与网络Meta分析,纳入成人中重度溃疡性结肠炎随机对照试验,评估抗TNF药物、抗整合素药物和JAK抑制剂作为一线或二线药物与安慰剂或其他活性药物比较。
  • 生物制剂初治患者纳入12项试验,无头对头比较。
  • 既往暴露于抗TNF患者纳入4项试验,无头对头比较。
  • 使用GRADE方法评估证据质量。

主要发现

  • 生物制剂初治患者中,英夫利西单抗诱导临床缓解的OR为4.10(95%CI 2.58-6.52),SUCRA为0.85;维得利珠单抗SUCRA为0.82。
  • 生物制剂初治患者中,英夫利西单抗黏膜愈合SUCRA为0.91,维得利珠单抗SUCRA为0.81。
  • 既往暴露于抗TNF患者中,托法替尼诱导临床缓解的OR为11.88(95%CI 2.32-60.89),SUCRA为0.96。
  • 维持治疗试验中,维得利珠单抗在严重不良事件方面SUCRA为0.91,在感染方面SUCRA为0.75,排名最安全。

关键数值与推荐

  • 生物制剂初治患者诱导临床缓解和黏膜愈合的证据质量为中等。
  • 既往暴露于抗TNF患者诱导临床缓解和黏膜愈合的证据质量为中等。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 生物制剂初治患者和既往暴露于抗TNF患者的试验均无头对头比较。
  • 试验设计的差异限制了维持治疗疗效试验的可比性。
  • 需要头对头试验以更有信心地为临床决策提供信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe ulcerative colitis (UC). AIM: To assess comparative efficacy and safety of different therapies as first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor(TNF)-α) agents for moderate-severe UC, through a systematic review and network meta-analysis, and appraise quality of evidence (QoE) using grading of recommendations, assessment, development and evaluation (GRADE) approach. METHODS: We identified randomised controlled trials (RCTs) in adults with moderate-severe UC treated with anti-TNF agents, anti-integrin agents and janus kinase (JAK) inhibitors, as first-line or second-line agents, and compared with placebo or another active agent. Efficacy outcomes were induction/maintenance of remission and mucosal healing; and safety outcomes were serious adverse events and infections. Network meta-analyses were performed, and ranking was assessed using surface under the cumulative ranking (SUCRA) probabilities. RESULTS: In biologic-naïve patients (12 trials, no head-to-head comparisons), infliximab and vedolizumab were ranked highest for induction of clinical remission (infliximab: odds ratio [OR], 4.10 [95% confidence intervals [CI], 2.58-6.52]; SUCRA,0.85; vedolizumab:SUCRA,0.82) and mucosal healing (infliximab:SUCRA,0.91; vedolizumab:SUCRA,0.81) (moderate QoE). In patients with prior anti-TNF exposure (4 trials, no head-to-head comparisons), tofacitinib was ranked highest for induction of clinical remission (OR, 11.88 [2.32-60.89]; SUCRA, 0.96) and mucosal healing (moderate QoE). Differences in trial design limited comparability of trials of maintenance therapy for efficacy. Vedolizumab was ranked safest in terms of serious adverse events (SUCRA, 0.91), and infection (SUCRA, 0.75) in maintenance trials. CONCLUSIONS: Infliximab and vedolizumab are ranked highest as first-line agents, and tofacitinib is ranked highest as second-line agent, for induction of remission and mucosal healing in patients with moderate-severe UC, based on indirect comparisons. Head-to-head trials are warranted to inform clinical decision-making with greater confidence.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Singh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2017. PMID: 29205406. doi:10.1111/apt.14422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。